Lawrence Fong, MD

Columbia University, New York, NY, BA, 1984-1988, Pre-Med., Economics
Stanford University, Stanford, CA, MD, 1988-1992

• 1992-1993
  Intern in Internal Medicine, University of Washington Medical Center.
• 1993-1994
  Resident in Internal Medicine, University of Washington Medical Center.
• 1994-1997
  Fellow in Medical Oncology, Stanford University School of Medicine.
• 1996-2001
  Post-Doctoral Fellow, Department of Pathology, Stanford University School of Medicine. Mentor: Edgar Engleman, MD.
• 1997-2002
  Staff Physician, Division of Medical Oncology, Stanford University School of Medicine.
• 2001-2002
  Acting Assistant Professor, Department of Pathology, Stanford University School of Medicine. Mentor: Mark M. Davis, PhD
• 2002-2008
  Assistant Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco.
• 2008-present
  Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco.

• 1990
  Stanford Alumni Medical Scholar
• 1993
  Alpha Omega Alpha
• 1997
  American Society of Clinical Oncology Young Investigator Award
• 1997
  American Cancer Society Post-Doctoral Fellowship Award
• 1997
  American Association for Cancer Research AFLAC Award
• 2002
  American Association for Cancer Research Scholar-in-Training Award
• 2003
  V Foundation Scholar

• Kim DT, Mitchell D, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. Introduction of soluble proteins into both MHC class I and II pathways by conjugation to a HIV tat peptide. J Immunol 159:1666-68,1997.
• Fong L, Ruegg C, Brockstedt DG, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: Implications for prostate cancer immunotherapy. J Immunol 159:3113-3118, 1997.
• Hayamizu K, Zeng D, Huie P, Garcia-Ojeda ME, Bloch DA, Fong L, Engleman EG, Sibley RK, Strober S. Donor blood monocytes but not T or B cells facilitate long-term allograft survival after total lymphoid irradiation. Transplantation 66(5):585-93, 1998.
• Brockstedt DG, Podsakoff GM, Fong L, Kurtzman G, Mueller-Ruchholtz W, Engleman EG. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin Immunol 92(1):67-75, 1999.
• Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5(6):677-685, 1999.
• Fong L and Engleman EG. Dendritic cells in cancer immunotherapy. Ann Rev Immunol 18:245-273, 2000.
• Merad M, Fong L, Bogenberger J, Engleman EG. Differentiation of myeloid dendritic cells into CD8-positive dendritic cells in vivo. Blood 96(5):1865-72, 2000.
• Fong L, Brockstedt DG, Benike C, Wu L, Engleman EG. Induction of immunity with dendritic cells administered via different routes in cancer patients. J Immunol. 166: 4254-4259, 2001.
• Fong L, Hao Y, Rivas A, Benike C, Yuen A, Fisher G, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci 98(15):8809-14, 2001.
• Fong L, Benike C, Strang G, Smits B, Ruegg CL, Engleman EG. Immunotherapy with xenoantigen loaded dendritic cells in prostate cancer patients. J Immunol 167: 7150-7156, 2001.
• Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic antitumor immunity. Blood 99(5):1676-82, 2002.
• Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol 76(21):11033-41, 2002.
• Engleman EG, Fong L. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients. Clin Immunol 106(1):10-5, 2003.
• Fong L, Small EJ. Immunotherapy for prostate cancer. Curr Urol Rep. 7(3):239-46, 2006.
• Rini BI, Fong L, Weinberg V, Kavanagh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6):2087-91, 2006.
• Rini BI, Weinberg V, Fong L, Conry S, Hershberg R, and Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107(1):67-74, 2006.
• Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, and Wilding G, A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen-Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer. Mol Ther; 14(1):107-17, 2006.
• Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 98(4):763-9, 2006.
• Devoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med; 203(12):2727-35, 2006.
• Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer. Clin Cancer Res; 13(6):1810-5, 2007.
• Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Shilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunoth, 30(7):762-772, 2007.
• Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Phase II study of ketoconazole plus GM-CSF in hormone refractory prostate cancer: Effect of extent of disease on outcome. J Urol, 178(6):2372-6, 2007.
• Hou Y, Kavanagh B, Fong L. Distinct CD8+ T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol, 180(3):1526-34, 2008.
• Fasso M, Waitz R, Rim T, Hou Y, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma specific T cells-1)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci,105(9):3509-14, 2008.